Patents by Inventor Leigh Zawel

Leigh Zawel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220296581
    Abstract: The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.
    Type: Application
    Filed: June 6, 2022
    Publication date: September 22, 2022
    Applicants: NOVARTIS AG, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Leigh ZAWEL, Christopher S. STRAUB, Brant G. FIRESTONE, Glenn DRANOFF, Michael DOUGAN
  • Patent number: 11382905
    Abstract: The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: July 12, 2022
    Assignees: NOVARTIS AG, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Leigh Zawel, Christopher S. Straub, Brant G. Firestone, Glenn Dranoff, Michael Dougan
  • Publication number: 20200345714
    Abstract: The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.
    Type: Application
    Filed: July 13, 2020
    Publication date: November 5, 2020
    Applicants: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Leigh ZAWEL, Christopher S. STRAUB, Brant G. FIRESTONE, Glenn DRANOFF, Michael DOUGAN
  • Patent number: 10786491
    Abstract: The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: September 29, 2020
    Assignees: NOVARTIS AG, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Leigh Zawel, Christopher S. Straub, Brant G. Firestone, Glenn Dranoff, Michael Dougan
  • Publication number: 20170368047
    Abstract: The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.
    Type: Application
    Filed: August 14, 2017
    Publication date: December 28, 2017
    Inventors: Leigh ZAWEL, Christopher S. STRAUB, Brant G. FIRESTONE, Glenn DRANOFF, Michael DOUGAN
  • Patent number: 9750729
    Abstract: The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: September 5, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., Novartis AG
    Inventors: Leigh Zawel, Christopher S. Straub, Brant G. Firestone, Glenn Dranoff, Michael Dougan
  • Patent number: 8906936
    Abstract: The invention provides a pharmaceutical combination comprising: a) compounds that inhibit the binding of the Smac protein to IAPs; and b) a taxane, and a method for treating or preventing a proliferative disease using such a combination.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: December 9, 2014
    Assignee: Novartis AG
    Inventors: Michael Rugaard Jensen, Christopher Sean Straub, Leigh Zawel, Mary Ann Tran, Youzhen Wang
  • Publication number: 20140024687
    Abstract: The invention relates to combinations comprising a vascular disrupting agent (VDA) with IAP antagonists, for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of proliferative diseases.
    Type: Application
    Filed: September 20, 2013
    Publication date: January 23, 2014
    Inventors: Colleen Ann Conway, Brant Geoffrey Firestone, Leigh Zawel
  • Publication number: 20140004101
    Abstract: The present invention is directed to a compound of the formula: or pharmaceutically acceptable salts thereof and use of such compounds for treating proliferative diseases such as cancer, in mammals.
    Type: Application
    Filed: August 29, 2013
    Publication date: January 2, 2014
    Applicant: NOVARTIS AG
    Inventors: Zhuoliang Chen, Christine Hiu-Tung Chen, Mark G. Charest, Miao Dai, Feng He, Lei Huangshu, Ly Luu Pham, Sushil Kumar Sharma, Christopher Sean Straub, Run-Ming David Wang, Fan Yang, Leigh Zawel
  • Patent number: 8552003
    Abstract: The present invention is directed to a compound of the formula: or pharmaceutically acceptable salts thereof and use of such compounds for treating proliferative diseases such as cancer, in mammals.
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: October 8, 2013
    Assignee: Novartis AG
    Inventors: Mark G. Charest, Christine Hiu-Tung Chen, Zhuoliang Chen, Miao Dai, Feng He, Huangshu Lei, Ly Luu Pham, Sushil Kumar Sharma, Christopher Sean Straub, Run-Ming David Wang, Fan Yang, Leigh Zawel
  • Patent number: 8546336
    Abstract: The present invention is directed to a compound of the formula: or pharmaceutically acceptable salts thereof and use of such compounds for treating proliferative diseases such as cancer, in mammals.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: October 1, 2013
    Assignee: Novartis AG
    Inventors: Zhuoliang Chen, Mark G. Charest, Christine Hiu-Tung Chen, Miao Dai, Feng He, Huangshu Lei, Ly Luu Pham, Sushil Kumar Sharma, Christopher Sean Straub, Run-Ming David Wang, Fan Yang, Leigh Zawel
  • Patent number: 8492429
    Abstract: The present invention relates to methods of treating hematological malignancies, including acute myeloid leukemia (AML), comprising the combination of a compound that inhibits the binding of the Smac protein to IAPs (“IAP inhibitor”) and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; and a commercial package comprising said combination. The present invention also relates to the use of IAP inhibitors in combination with one or more pharmaceutically active agents for the preparation of a medicament to treat hematological malignancies, including AML.
    Type: Grant
    Filed: November 27, 2007
    Date of Patent: July 23, 2013
    Assignee: Novartis AG
    Inventors: James Douglas Griffin, Leigh Zawel
  • Publication number: 20130085153
    Abstract: The invention provides a pharmaceutical combination comprising: a) compounds that inhibit the binding of the Smac protein to IAPs; and b) a taxane, and a method for treating or preventing a proliferative disease using such a combination.
    Type: Application
    Filed: July 12, 2012
    Publication date: April 4, 2013
    Inventors: Michael Rugaard Jensen, Christopher Sean Straub, Leigh Zawel, Mary Ann Tran, Youzhen Wang
  • Publication number: 20130005663
    Abstract: The present invention is directed to a compound of the formula: or pharmaceutically acceptable salts thereof and use of such compounds for treating proliferative diseases such as cancer, in mammals.
    Type: Application
    Filed: September 7, 2012
    Publication date: January 3, 2013
    Applicant: NOVARTIS AG
    Inventors: Mark G. CHAREST, Christine Hiu-Tung CHEN, Zhuoliang CHEN, Miao DAI, Feng HE, Huangshu LEI, Ly Luu PHAM, Sushil Kumar SHARMA, Christopher Sean STRAUB, Run-Ming David WANG, Fan YANG, Leigh ZAWEL
  • Patent number: 8338440
    Abstract: Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula (I).
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: December 25, 2012
    Inventors: Mark G. Palermo, Sushil Kumar Sharma, Christopher Sean Straub, Run-Ming Wang, Leigh Zawel, Yanlin Zhang, Zhuoliang Chen, Yaping Wang, Fan Yang, Wojciech Wrona, Gang Liu, Mark G. Charest, Feng He
  • Publication number: 20120207769
    Abstract: Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula (I).
    Type: Application
    Filed: April 26, 2012
    Publication date: August 16, 2012
    Applicant: NOVARTIS AG
    Inventors: Mark G. PALERMO, Sushil Kumar SHARMA, Christopher STRAUB, Run-Ming WANG, Leigh ZAWEL, Yanlin ZHANG, Zhuoliang CHEN, Yaping WANG, Fan YANG, Wojciech WRONA, Gang LIU, Mark G. CHAREST, Feng HE
  • Publication number: 20120196793
    Abstract: A method to predict which patients will respond to a IAP inhibiting compound comprising administering an IAP inhibitor compound to a patient/and measuring IL1B, Lymphotoxin alpha (LTa), TWEAK, LIGHT, Fas, TNF alpha or TRAIL levels.
    Type: Application
    Filed: September 17, 2010
    Publication date: August 2, 2012
    Inventors: Brant G. Firestone, Kymberly Levine, Dale A. Porter, John Sullivan, Leigh Zawel
  • Patent number: 8207183
    Abstract: Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula (I).
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: June 26, 2012
    Assignee: Novartis AG
    Inventors: Mark G. Palermo, Sushil Kumar Sharma, Christopher Sean Straub, Run-Ming Wang, Leigh Zawel, Yanling Zhang, Zhuoliang Chen, Yaping Wang, Fan Yang, Wojciech Wrona, Gang Liu, Mark G. Charest, Feng He
  • Publication number: 20120129895
    Abstract: The invention relates to combinations comprising a vascular disrupting agent (VDA) with IAP antagonists, for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of proliferative diseases.
    Type: Application
    Filed: August 11, 2010
    Publication date: May 24, 2012
    Inventors: Colleen Conway, Brant Geoffrey Firestone, Leigh Zawel
  • Publication number: 20110319614
    Abstract: The present invention relates to novel IAP inhibitor compounds of formula I:
    Type: Application
    Filed: September 8, 2011
    Publication date: December 29, 2011
    Applicant: NOVARTIS AG
    Inventors: Zhuoliang CHEN, Run-Ming David WANG, Ming CHEN, Christopher Sean STRAUB, Leigh ZAWEL